Shots:
David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV studyÂ
SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patientsÂ
SHAMAL showcased that ICS…
